A Phase 1 interventional study of crizotinib and crizotinib in Advanced Cancer, sponsored by Pfizer. Completed at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-25.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is designed to evaluate the potential effect of hepatic impairment on the pharmacokinetics and safety of crizotinib in advanced cancer patients. Advanced cancer patients with mild, moderate or severe liver dysfunction as well as patients with normal liver function will be enrolled in this study.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
or cytologically confirmed solid or lymphoma that is or unresectable, and for which standard curative or palliative measures do not exist, or are no longer effective. In case of hepatocellular carcinoma, the diagnosis should be based on at least one of the following:
Bone marrow function
Creatinine ≤ 1.5 x or > 60 mL/min/1.73 m2 for patients with serum creatinine levels above institutional 1.5 x ULN
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: crizotinib
Drug: crizotinib
Drug: crizotinib
Drug: crizotinib
Drug: crizotinib
crizotinib 250 mg twice a day
crizotinib 250 mg once a day
crizotinib 250 mg twice a day
crizotinib 250 mg once a day
crizotinib 250 mg once a day
Area Under Plasma Concentration Time Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib: Cycle 2 Day 1
Area under the plasma concentration-time curve from time zero to the quantifiable concentration at the end of dosing interval (tau hours post-dose, where tau was 12 hours for twice daily dosing and 24 hours for once daily dosing) of Cycle 2 Day 1.
Time frame: Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Maximum Observed Plasma Concentration (Cmax) of Crizotinib: Cycle 2 Day 1
Time frame: Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Plasma Concentration (AUClast) of Crizotinib: Cycle 1 Day 1
Time frame: Cycle 1 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Maximum Observed Plasma Concentration (Cmax) of Crizotinib: Cycle 1 Day 1
Time frame: Cycle 1 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib: Cycle 1 Day 1
Time frame: Cycle 1 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Minimum Observed Plasma Concentration (Cmin) of Crizotinib: Cycle 2 Day 1
Time frame: Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Plasma Concentration (AUClast) of Crizotinib: Cycle 2 Day 1
Time frame: Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Plasma Accumulation Ratio (Rac) of Crizotinib
Rac was defined as the ratio of AUCtau of Cycle 2 Day 1 to AUCtau of Cycle 1 Day 1, where AUCtau was area under the plasma concentration-time curve from time zero to the quantifiable concentration at the end of dosing interval (tau hours post-dose, where tau was 12 hours for twice daily dosing and 24 hours for once daily dosing).
Time frame: Cycle 1 Day 1 and Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Apparent Oral Clearance (CL/F) of Crizotinib: Cycle 2 Day 1
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent oral clearance was obtained by dividing study drug dose with AUCtau, where AUCtau was area under the plasma concentration-time curve from time zero to the quantifiable concentration at the end of dosing interval (tau hours post-dose, where tau was 12 hours for twice daily dosing and 24 hours for once daily dosing) of Cycle 2 Day 1.
Time frame: Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Fraction of Unbound Crizotinib in Plasma: Cycle 2 Day 1
Fraction of unbound Crizotinib concentration in plasma was defined as the ratio of unbound Crizotinib concentration to the total Crizotinib concentration.
Time frame: Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Unbound Area Under the Plasma Concentration Time Curve From Time Zero to the Last Quantifiable Plasma Concentration (AUClast) of Crizotinib: Cycle 2 Day 1
Unbound area under the plasma concentration-time curve from time zero to the last quantifiable plasma concentration post-dose of Cycle 2 day 1.
Time frame: Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Unbound Area Under Plasma Concentration-Time Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib: Cycle 2 Day 1
Unbound area under the plasma concentration-time curve from time zero to the quantifiable concentration at the end of dosing interval (tau hours post-dose, where tau was 12 hours for twice daily dosing and 24 hours for once daily dosing) of Cycle 2 Day 1.
Time frame: Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Unbound Maximum Observed Plasma Concentration (Cmax) of Crizotinib: Cycle 2 Day 1
Time frame: Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Area Under Plasma Concentration Time Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06260182: Cycle 2 Day 1
Area under the plasma concentration-time curve from time zero to the quantifiable concentration at the end of dosing interval (tau hours postdose, where tau was 12 hours for twice daily dosing and 24 hours for once daily dosing) of Cycle 2 Day 1. AUCtau of PF-06260182, (a metabolite of Crizotinib) is reported in this outcome measure.
Time frame: Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Plasma Concentration (AUClast) of PF-06260182: Cycle 1 Day 1
AUClast of PF-06260182, (a metabolite of Crizotinib) is reported in this outcome measure.
Time frame: Cycle 1 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Maximum Observed Plasma Concentration (Cmax) of PF-06260182: Cycle 1 Day 1
Cmax of PF-06260182, (a metabolite of Crizotinib) is reported in this outcome measure.
Time frame: Cycle 1 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Maximum Observed Plasma Concentration (Cmax) of PF-06260182: Cycle 2 Day 1
Cmax of PF-06260182, (a metabolite of Crizotinib) is reported in this outcome measure.
Time frame: Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06260182: Cycle 1 Day 1
Tmax of PF-06260182, (a metabolite of Crizotinib) is reported in this outcome measure.
Time frame: Cycle 1 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06260182: Cycle 2 Day 1
Tmax of PF-06260182, (a metabolite of Crizotinib) is reported in this outcome measure.
Time frame: Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Metabolite Ratio for Area Under Plasma Concentration Time Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06260182: Cycle 2 Day 1
Metabolite ratio for AUCtau was defined as the ratio of AUCtau of metabolite (PF-06260182) to AUCtau of parent drug (Crizotinib), where AUCtau was the area under the plasma concentration-time curve from time zero to the quantifiable concentration at the end of dosing interval (tau was 12 hours for twice daily dosing and 24 hours for once daily dosing) of Cycle 2 Day 1.
Time frame: Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Metabolite Ratio for Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Plasma Concentration (AUClast) of PF-06260182: Cycle 1 Day 1
Metabolite ratio for AUClast was defined as the ratio of AUClast of metabolite (PF-06260182) to AUClast of parent drug (Crizotinib), where AUClast was area under the plasma concentration-time curve from time zero to the last quantifiable plasma concentration post-dose of Cycle 1 Day 1.
Time frame: Cycle 1 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Metabolite Ratio for Maximum Observed Plasma Concentration (Cmax) of PF-06260182: Cycle 1 Day 1
Metabolite ratio for Cmax was defined as the ratio of Cmax of metabolite (PF-06260182) to Cmax of parent drug (Crizotinib), where Cmax was maximum observed plasma concentration post-dose of Cycle 1 Day 1.
Time frame: Cycle 1 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Metabolite Ratio for Maximum Observed Plasma Concentration (Cmax) of PF-06260182: Cycle 2 Day 1
Metabolite ratio for Cmax was defined as the ratio of Cmax of metabolite (PF-06260182) to Cmax of parent drug (Crizotinib), where Cmax was maximum observed plasma concentration post-dose of Cycle 2 Day 1.
Time frame: Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Fraction of Unbound PF-06260182 in Plasma: Cycle 2 Day 1
Fraction of unbound PF-06260182 (a metabolite of Crizotinib) in plasma was defined as the ratio of unbound PF-06260182 concentration in plasma to the total PF-06260182 concentration.
Time frame: Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Unbound Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Plasma Concentration (AUClast) of PF-06260182: Cycle 2 Day 1
Unbound AUClast of PF-06260182 (a metabolite of Crizotinib) is reported in this outcome measure.
Time frame: Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Unbound Area Under Plasma Concentration Time Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06260182: Cycle 2 Day 1
Unbound area under the plasma concentration-time curve from time zero to the quantifiable concentration at the end of dosing interval (tau hours post-dose, where tau was 12 hours for twice daily dosing and 24 hours for once daily dosing) of Cycle 2 Day 1. Unbound AUCtau of PF-06260182, (a metabolite of Crizotinib) is reported in this outcome measure.
Time frame: Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Unbound Maximum Observed Plasma Concentration (Cmax) of PF-06260182: Cycle 2 Day 1
Unbound Cmax of PF-06260182, (a metabolite of Crizotinib) is reported in this outcome measure.
Time frame: Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Area Under the Plasma Concentration Time Curve as Daily Exposure (AUCdaily) of Crizotinib: Cycle 2 Day 1
Time frame: Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Unbound Area Under the Plasma Concentration Time Curve as Daily Exposure (AUCdaily) of Crizotinib: Cycle 2 Day 1
Time frame: Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Area Under the Plasma Concentration Time Curve as Daily Exposure (AUCdaily) of PF-06260182: Cycle 2 Day 1
AUCdaily of PF-06260182, (a metabolite of Crizotinib) is reported in this outcome measure.
Time frame: Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Unbound Area Under the Plasma Concentration Time Curve as Daily Exposure (AUCdaily) of PF-06260182: Cycle 2 Day 1
Unbound AUCdaily of PF-06260182, (a metabolite of Crizotinib) is reported in this outcome measure, where AUCdaily was area under the plasma concentration time curve as daily exposure post-dose.
Time frame: Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability or incapacity, congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 4 years that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious adverse events.
Time frame: From initiation of treatment up to follow-up period (up to 4 years)
Number of Participants With Treatment-Emergent Adverse Events, by National Cancer Institute (NCI) Common Terminology Criteria (CTC) for AEs (CTCAE) (Version 4.0) Grade
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AE was assessed according to severity grading based on National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events \[CTCAE\] Version 4.0. Grade 1 =mild; Grade 2 =moderate; Grade 3 =severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated; Grade 4 =life-threatening or disabling, urgent intervention indicated; Grade 5 =death. Treatment-emergent events were events between first dose of study drug and up to 4 years that were absent before treatment that worsened relative to pretreatment state. If the same participant in a given treatment had more than 1 adverse event, only the maximum CTCAE was reported.
Time frame: From initiation of treatment up to follow-up period (up to 4 years)
Number of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)
Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both serious and non-serious adverse events.
Time frame: From initiation of treatment up to follow-up period (up to 4 years)
Number of Participants With Laboratory Test Abnormalities: NCI CTCAE (Version 4.0) Grade 1 to 4 Hematological Test Abnormalities
Anemia(grade\[g\]1:Less than\[\<\] Lower limit of normal\[LLN\] to 10gram per\[/\] deciliter\[g/dL\],g2:\<10 to 8g/dL,g3:\<8g/dL,g4:lifethreatening);platelet (g1:\<LLN to 75\*10\^3/millimeter\[mm\]\^3,g2:\<75\*10\^3/mm\^3 to 50\*10\^3/mm\^3,g3:\<50\*10\^3/mm\^3 to 25\*10\^3/mm\^3,g4:\<25\*10\^3/mm\^3);lymphopenia(g1:\<LLN to 8\*10\^2/mm\^3,g2:\<8\*10\^2 to 5\*10\^2/mm\^3,g3:\<5\*10\^2 to 2\*10\^2/mm\^3,g4:\<2\*10\^2/mm\^3);neutrophil (Absolute)(g1:\<LLN to 15\*10\^2/mm\^3,g2:\<15\*10\^2 to 10\*10\^2/mm\^3,g3:\<10\*10\^2 to 5\*10\^2/mm\^3,g4:\<5\*10\^2/mm\^3);white blood cell count(g1:\<LLN to 3\*10\^3/mm\^3,g2:\<3\*10\^3 to 2\*10\^3/mm\^3,g3:\<2\*10\^3 to 1\*10\^3/mm\^3,g4:\<1\*10\^3/mm\^3);hemoglobin(g1:increase in hemoglobin level\>0 to 2 g/dL above ULN or above baseline if baseline is above ULN,g2:increase in hemoglobin level\>2 to 4g/dL above ULN or above baseline if baseline is above ULN,g3:increase in hemoglobin level\>4 g/dL above ULN or above baseline if baseline is above ULN). Only categories with atleast 1 participant with abnormality are reported in this outcome measure.
Time frame: Baseline up to end of treatment (up to 728 days)
Number of Participants With Laboratory Test Abnormalities: NCI CTCAE (Version 4.0) Grade 1 to 4 Chemistry Test Abnormalities
ALT/AST(grade\[g\]1:\>ULN-3\*ULN,g2:\>3-5\*ULN,g3:\>5-20\*ULN,g4:\>20\*ULN);AP(g1:\>ULN-2.5\*ULN,g2:\>2.5-5\*ULN,g3:\>5-20\*ULN,g4:\>20\*ULN);CR(g1:\>ULN-1.5\*ULN,g2:\>1.5-3\*ULN,g3:\>3-6\*ULN,g4:\>6\*ULN);hyperglycemia(g1:\>ULN-160mg/dL,g2:\>160-250mg/dL,g3:\>250-500mg/dL,g4:\>500mg/dL);bilirubin(total)(g1:\>ULN-1.5\*ULN,g2:\>1.5-3\*ULN,g3:\>3-10\*ULN,g4:\>10\*ULN);hypoglycemia(g1:\<LLN-55mg/dL,g2:\<55-40mg/dL,g3:\<40-30mg/dL,g4:\<30mg/dL);hyperkalemia(g1:\>ULN-5.5mmol/L,g2:\>5.5-6mmol/L,g3:\>6-7mmol/L,g4:\>7mmol/L);hypokalemia(g1:\<LLN-3mmol/L,g2:\<LLN-3mmol/L,g3:\<3-2.5mmol/L,g4:\<2.5mmol/L);hypermagnesemia(g1:\>ULN-3mg/dL,g3:\>3-8mg/dL,g4:\>8mg/dL);hypocalcemia(g1:\<LLN-8mg/dL,g2:\<8-7mg/dL,g3:\<7-6mg/dL,g4:\<6mg/dL);hypomagnesemia(g1:\<LLN-1.2mg/dL,g2:\<1.2-0.9mg/dL,g3:\<0.9-0.7mg/dL,g4:\<0.7mg/dL);hyponatremia(g1:\<LLN-130mmol/L,g3:\<130-120mmol/L,g4:\<120mmol/L);hypoalbuminemia(g1:\<LLN-3g/dL,g2:\<3-2g/dL,g3:\<2g/dL,g4:lifethreatening);hypophosphatemia(g1:\<LLN-2.5mg/dL,g2:\<2.5-2mg/dL,g3:\<2-1mg/dL,g4:\<1mg/dL).Participant\>=1abnormality given.
Time frame: Baseline up to end of treatment (up to 728 days)
Number of Participants With Abnormal Electrocardiogram (ECG) Findings
Criteria for abnormal value of ECG parameters: maximum increase from baseline (IFB) in QT interval using Fridericia's correction (QTcF)/QT interval using Bazett's correction (QTcB) range from less than (\<)30 millisecond (msec), 30 to \<60, greater than or equal to (\>=)60 msec; maximum post-dose QTcF/QTcB ranges from \<450 msec, 450 to \<480 msec, 480 to \<500, and \>=500 msec; PR interval: \>=50 percent (%) increase when baseline \<200 msec; or increase \>=25% when baseline less than or equal to (\<=)200 msec; QRS interval: \>=50% increase when baseline \<100 msec; \>=25% increase when baseline \>=100 msec. Only categories which included atleast 1 participant with abnormality are reported in this outcome measure.
Time frame: Baseline up to end of treatment (up to 728 days)
Number of Participants With Abnormal Fundoscopy Examination Findings
Fundoscopy examination included an examination of the vitreous body, retina macula, retina non-macula, optic nerve head, optic disc notching and fundus using the category of the examination status (normal, mild, moderate, or severe). In this outcome measure, number of participants with abnormal fundoscopy values identified by investigator were reported.
Time frame: Baseline up to end of treatment (up to 728 days)
Objective Response Rate (ORR)
ORR was defined as percentage of participants with confirmed complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumors (RECIST) version 1.1. In case of target lesions CR was defined as the disappearance of all target lesions and in case nodal disease included in the sum of target lesions. The nodes decreased to normal size (\<10 mm). In case of non-target lesions disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10 mm short axis). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Confirmed responses were those who persisted on repeat imaging study at least 4 weeks after the initial documentation of response.
Time frame: Baseline, every 8 weeks until disease progression or unacceptable toxicity up to end of treatment (up to 728 days)
Duration of Response (DR)
DR was defined as the time from date of first documentation of CR or PR to first documentation of objective tumor progression or death due to any cause, whichever occurred first. In case of target lesions CR was defined as the disappearance of all target lesions and in case nodal disease included in the sum of target lesions. The nodes decreased to normal size (\<10 mm). In case of non-target lesions disappearance of all non-target lesions and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Objective tumor progression as per RECIST version 1.1 was defined as \>=20% increase in sum of diameters of target lesions taking as a reference smallest sum of diameters recorded since treatment started, or appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. DR was estimated using Kaplan-Meier method.
Time frame: Baseline, every 8 weeks until disease progression or unacceptable toxicity up to end of treatment (up to 728 days)
| Milestone | Normal Hepatic Function: Crizotinib 250 mg Twice Daily | Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily | Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily | Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily | Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily | Severe Hepatic Impairment Crizotinib 250 mg Once Daily |
|---|---|---|---|---|---|---|
| Started | 11 | 15 | 20 | 10 | 16 | 16 |
| Completed | 5 | 7 | 4 | 1 | 8 | 4 |
| Not completed | 6 | 8 | 16 | 9 | 8 | 12 |
| Withdrew: Lost to follow-up | 1 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 3 | 4 | 8 | 5 | 7 | 9 |
| Withdrew: Non-clinical trial supply of crizotinib | 0 | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Withdrawal the consent | 2 | 2 | 5 | 1 | 1 | 3 |
| Withdrew: Other | 0 | 0 | 2 | 2 | 0 | 0 |
Area under the plasma concentration-time curve from time zero to the quantifiable concentration at the end of dosing interval (tau hours post-dose, where tau was 12 hours for twice daily dosing and 24 hours for once daily dosing) of Cycle 2 Day 1.
| nanogram*hour per milliliter (ng*hr/mL) | Normal Hepatic Function: Crizotinib 250 mg Twice Daily | Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily | Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily | Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily | Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily | Severe Hepatic Impairment Crizotinib 250 mg Once Daily |
|---|---|---|---|---|---|---|
| Area Under Plasma Concentration Time Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib: Cycle 2 Day 1 | 3552 ± 48 | 2712 ± 66 | 3238 ± 73 | 2305 ± 83 | 4057 ± 58 | 4596 ± 63 |
| nanogram per milliliter (ng/mL) | Normal Hepatic Function: Crizotinib 250 mg Twice Daily | Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily | Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily | Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily | Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily | Severe Hepatic Impairment Crizotinib 250 mg Once Daily |
|---|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Crizotinib: Cycle 2 Day 1 | 375.1 ± 50 | 283.9 ± 65 | 342.1 ± 68 | 152.9 ± 58 | 408.3 ± 56 | 272.4 ± 29 |
| ng*hr/mL | Normal Hepatic Function: Crizotinib 250 mg Twice Daily | Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily | Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily | Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily | Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily | Severe Hepatic Impairment Crizotinib 250 mg Once Daily |
|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Plasma Concentration (AUClast) of Crizotinib: Cycle 1 Day 1 | 732.3 ± 84 | 520.8 ± 49 | 557.5 ± 78 | 610.4 ± 128 | 684.9 ± 89 | 856.7 ± 57 |
| ng/mL | Normal Hepatic Function: Crizotinib 250 mg Twice Daily | Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily | Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily | Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily | Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily | Severe Hepatic Impairment Crizotinib 250 mg Once Daily |
|---|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Crizotinib: Cycle 1 Day 1 | 101.9 ± 92 | 84.52 ± 67 | 102.3 ± 66 | 57.74 ± 112 | 99.59 ± 88 | 90.69 ± 63 |
| hour | Normal Hepatic Function: Crizotinib 250 mg Twice Daily | Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily | Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily | Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily | Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily | Severe Hepatic Impairment Crizotinib 250 mg Once Daily |
|---|---|---|---|---|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib: Cycle 1 Day 1 | 4.00 (1.00 to 6.00) | 4.00 (1.00 to 6.00) | 4.00 (1.92 to 10.9) | 2.02 (1.00 to 4.05) | 4.00 (1.00 to 8.00) | 3.00 (1.00 to 6.00) |
| ng/mL | Normal Hepatic Function: Crizotinib 250 mg Twice Daily | Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily | Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily | Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily | Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily | Severe Hepatic Impairment Crizotinib 250 mg Once Daily |
|---|---|---|---|---|---|---|
| Minimum Observed Plasma Concentration (Cmin) of Crizotinib: Cycle 2 Day 1 | 238.6 ± 52 | 170.9 ± 75 | 179.1 ± 101 | 47.44 ± 376 | 287.0 ± 58 | 135.5 ± 102 |
No measurements were reported for this outcome.
Rac was defined as the ratio of AUCtau of Cycle 2 Day 1 to AUCtau of Cycle 1 Day 1, where AUCtau was area under the plasma concentration-time curve from time zero to the quantifiable concentration at the end of dosing interval (tau hours post-dose, where tau was 12 hours for twice daily dosing and 24 hours for once daily dosing).
No measurements were reported for this outcome.
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent oral clearance was obtained by dividing study drug dose with AUCtau, where AUCtau was area under the plasma concentration-time curve from time zero to the quantifiable concentration at the end of dosing interval (tau hours post-dose, where tau was 12 hours for twice daily dosing and 24 hours for once daily dosing) of Cycle 2 Day 1.
| Liter/hour | Normal Hepatic Function: Crizotinib 250 mg Twice Daily | Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily | Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily | Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily | Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily | Severe Hepatic Impairment Crizotinib 250 mg Once Daily |
|---|---|---|---|---|---|---|
| Apparent Oral Clearance (CL/F) of Crizotinib: Cycle 2 Day 1 | 70.39 ± 48 | 73.79 ± 66 | 77.21 ± 73 | 108.5 ± 83 | 49.26 ± 58 | 54.36 ± 63 |
Fraction of unbound Crizotinib concentration in plasma was defined as the ratio of unbound Crizotinib concentration to the total Crizotinib concentration.
| ratio | Normal Hepatic Function: Crizotinib 250 mg Twice Daily | Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily | Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily | Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily | Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily | Severe Hepatic Impairment Crizotinib 250 mg Once Daily |
|---|---|---|---|---|---|---|
| Fraction of Unbound Crizotinib in Plasma: Cycle 2 Day 1 | 0.03624 ± 26 | 0.03066 ± 27 | 0.04315 ± 31 | 0.05406 ± 20 | 0.04152 ± 34 | 0.03523 ± 46 |
Unbound area under the plasma concentration-time curve from time zero to the last quantifiable plasma concentration post-dose of Cycle 2 day 1.
No measurements were reported for this outcome.
Unbound area under the plasma concentration-time curve from time zero to the quantifiable concentration at the end of dosing interval (tau hours post-dose, where tau was 12 hours for twice daily dosing and 24 hours for once daily dosing) of Cycle 2 Day 1.
| ng*hr/mL | Normal Hepatic Function: Crizotinib 250 mg Twice Daily | Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily | Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily | Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily | Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily | Severe Hepatic Impairment Crizotinib 250 mg Once Daily |
|---|---|---|---|---|---|---|
| Unbound Area Under Plasma Concentration-Time Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib: Cycle 2 Day 1 | 128.7 ± 38 | 83.08 ± 73 | 139.7 ± 94 | 124.6 ± 85 | 168.6 ± 59 | 161.9 ± 48 |
| ng/mL | Normal Hepatic Function: Crizotinib 250 mg Twice Daily | Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily | Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily | Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily | Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily | Severe Hepatic Impairment Crizotinib 250 mg Once Daily |
|---|---|---|---|---|---|---|
| Unbound Maximum Observed Plasma Concentration (Cmax) of Crizotinib: Cycle 2 Day 1 | 13.59 ± 41 | 8.703 ± 74 | 14.77 ± 93 | 8.271 ± 62 | 16.96 ± 56 | 9.608 ± 34 |
Area under the plasma concentration-time curve from time zero to the quantifiable concentration at the end of dosing interval (tau hours postdose, where tau was 12 hours for twice daily dosing and 24 hours for once daily dosing) of Cycle 2 Day 1. AUCtau of PF-06260182, (a metabolite of Crizotinib) is reported in this outcome measure.
| ng*hr/mL | Normal Hepatic Function: Crizotinib 250 mg Twice Daily | Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily | Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily | Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily | Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily | Severe Hepatic Impairment Crizotinib 250 mg Once Daily |
|---|---|---|---|---|---|---|
| Area Under Plasma Concentration Time Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06260182: Cycle 2 Day 1 | 1087 ± 43 | 717.4 ± 81 | 480.3 ± 168 | 200.0 ± 48 | 391.8 ± 118 | 434.0 ± 96 |
AUClast of PF-06260182, (a metabolite of Crizotinib) is reported in this outcome measure.
| ng*hr/mL | Normal Hepatic Function: Crizotinib 250 mg Twice Daily | Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily | Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily | Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily | Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily | Severe Hepatic Impairment Crizotinib 250 mg Once Daily |
|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Plasma Concentration (AUClast) of PF-06260182: Cycle 1 Day 1 | 272.4 ± 80 | 166.5 ± 31 | 90.71 ± 153 | 64.90 ± 103 | 53.36 ± 139 | 59.61 ± 81 |
Cmax of PF-06260182, (a metabolite of Crizotinib) is reported in this outcome measure.
| ng/mL | Normal Hepatic Function: Crizotinib 250 mg Twice Daily | Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily | Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily | Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily | Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily | Severe Hepatic Impairment Crizotinib 250 mg Once Daily |
|---|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of PF-06260182: Cycle 1 Day 1 | 35.48 ± 86 | 24.12 ± 33 | 13.54 ± 153 | 4.869 ± 95 | 6.995 ± 152 | 4.088 ± 88 |
Cmax of PF-06260182, (a metabolite of Crizotinib) is reported in this outcome measure.
| ng/mL | Normal Hepatic Function: Crizotinib 250 mg Twice Daily | Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily | Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily | Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily | Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily | Severe Hepatic Impairment Crizotinib 250 mg Once Daily |
|---|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of PF-06260182: Cycle 2 Day 1 | 108.5 ± 43 | 73.47 ± 76 | 50.34 ± 164 | 12.43 ± 55 | 39.32 ± 120 | 25.15 ± 110 |
Tmax of PF-06260182, (a metabolite of Crizotinib) is reported in this outcome measure.
| hour | Normal Hepatic Function: Crizotinib 250 mg Twice Daily | Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily | Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily | Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily | Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily | Severe Hepatic Impairment Crizotinib 250 mg Once Daily |
|---|---|---|---|---|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06260182: Cycle 1 Day 1 | 6.04 (4.00 to 8.00) | 4.00 (2.00 to 8.00) | 4.00 (4.00 to 10.9) | 6.08 (5.93 to 8.00) | 8.00 (4.00 to 12.00) | 7.00 (4.00 to 8.00) |
Tmax of PF-06260182, (a metabolite of Crizotinib) is reported in this outcome measure.
| hour | Normal Hepatic Function: Crizotinib 250 mg Twice Daily | Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily | Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily | Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily | Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily | Severe Hepatic Impairment Crizotinib 250 mg Once Daily |
|---|---|---|---|---|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06260182: Cycle 2 Day 1 | 6.00 (0.983 to 10.0) | 4.03 (1.00 to 7.45) | 4.00 (0 to 10.8) | 6.00 (4.05 to 7.30) | 0 (0 to 6.00) | 6.69 (0 to 8.00) |
Metabolite ratio for AUCtau was defined as the ratio of AUCtau of metabolite (PF-06260182) to AUCtau of parent drug (Crizotinib), where AUCtau was the area under the plasma concentration-time curve from time zero to the quantifiable concentration at the end of dosing interval (tau was 12 hours for twice daily dosing and 24 hours for once daily dosing) of Cycle 2 Day 1.
| ratio | Normal Hepatic Function: Crizotinib 250 mg Twice Daily | Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily | Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily | Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily | Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily | Severe Hepatic Impairment Crizotinib 250 mg Once Daily |
|---|---|---|---|---|---|---|
| Metabolite Ratio for Area Under Plasma Concentration Time Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06260182: Cycle 2 Day 1 | 0.2968 ± 17 | 0.2569 ± 31 | 0.1439 ± 74 | 0.08402 ± 65 | 0.09360 ± 47 | 0.09162 ± 47 |
Metabolite ratio for AUClast was defined as the ratio of AUClast of metabolite (PF-06260182) to AUClast of parent drug (Crizotinib), where AUClast was area under the plasma concentration-time curve from time zero to the last quantifiable plasma concentration post-dose of Cycle 1 Day 1.
| ratio | Normal Hepatic Function: Crizotinib 250 mg Twice Daily | Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily | Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily | Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily | Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily | Severe Hepatic Impairment Crizotinib 250 mg Once Daily |
|---|---|---|---|---|---|---|
| Metabolite Ratio for Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Plasma Concentration (AUClast) of PF-06260182: Cycle 1 Day 1 | 0.3608 ± 18 | 0.3104 ± 30 | 0.1577 ± 60 | 0.1032 ± 72 | 0.07566 ± 42 | 0.06753 ± 21 |
Metabolite ratio for Cmax was defined as the ratio of Cmax of metabolite (PF-06260182) to Cmax of parent drug (Crizotinib), where Cmax was maximum observed plasma concentration post-dose of Cycle 1 Day 1.
| ratio | Normal Hepatic Function: Crizotinib 250 mg Twice Daily | Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily | Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily | Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily | Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily | Severe Hepatic Impairment Crizotinib 250 mg Once Daily |
|---|---|---|---|---|---|---|
| Metabolite Ratio for Maximum Observed Plasma Concentration (Cmax) of PF-06260182: Cycle 1 Day 1 | 0.3378 ± 25 | 0.2769 ± 41 | 0.1284 ± 70 | 0.08178 ± 66 | 0.06809 ± 47 | 0.04373 ± 42 |
Metabolite ratio for Cmax was defined as the ratio of Cmax of metabolite (PF-06260182) to Cmax of parent drug (Crizotinib), where Cmax was maximum observed plasma concentration post-dose of Cycle 2 Day 1.
| ratio | Normal Hepatic Function: Crizotinib 250 mg Twice Daily | Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily | Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily | Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily | Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily | Severe Hepatic Impairment Crizotinib 250 mg Once Daily |
|---|---|---|---|---|---|---|
| Metabolite Ratio for Maximum Observed Plasma Concentration (Cmax) of PF-06260182: Cycle 2 Day 1 | 0.2804 ± 19 | 0.2511 ± 31 | 0.1428 ± 73 | 0.07881 ± 58 | 0.09337 ± 49 | 0.08954 ± 90 |
Fraction of unbound PF-06260182 (a metabolite of Crizotinib) in plasma was defined as the ratio of unbound PF-06260182 concentration in plasma to the total PF-06260182 concentration.
| ratio | Normal Hepatic Function: Crizotinib 250 mg Twice Daily | Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily | Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily | Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily | Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily | Severe Hepatic Impairment Crizotinib 250 mg Once Daily |
|---|---|---|---|---|---|---|
| Fraction of Unbound PF-06260182 in Plasma: Cycle 2 Day 1 | 0.03797 ± 11 | 0.03822 ± 16 | 0.04857 ± 16 | 0.05788 ± 22 | 0.05031 ± 10 | 0.05177 ± 13 |
Unbound AUClast of PF-06260182 (a metabolite of Crizotinib) is reported in this outcome measure.
No measurements were reported for this outcome.
Unbound area under the plasma concentration-time curve from time zero to the quantifiable concentration at the end of dosing interval (tau hours post-dose, where tau was 12 hours for twice daily dosing and 24 hours for once daily dosing) of Cycle 2 Day 1. Unbound AUCtau of PF-06260182, (a metabolite of Crizotinib) is reported in this outcome measure.
| ng*hr/mL | Normal Hepatic Function: Crizotinib 250 mg Twice Daily | Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily | Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily | Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily | Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily | Severe Hepatic Impairment Crizotinib 250 mg Once Daily |
|---|---|---|---|---|---|---|
| Unbound Area Under Plasma Concentration Time Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06260182: Cycle 2 Day 1 | 41.26 ± 36 | 27.40 ± 99 | 23.35 ± 181 | 11.56 ± 49 | 19.71 ± 119 | 22.49 ± 79 |
Unbound Cmax of PF-06260182, (a metabolite of Crizotinib) is reported in this outcome measure.
| ng/mL | Normal Hepatic Function: Crizotinib 250 mg Twice Daily | Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily | Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily | Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily | Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily | Severe Hepatic Impairment Crizotinib 250 mg Once Daily |
|---|---|---|---|---|---|---|
| Unbound Maximum Observed Plasma Concentration (Cmax) of PF-06260182: Cycle 2 Day 1 | 4.119 ± 36 | 2.806 ± 94 | 2.445 ± 178 | 0.7194 ± 50 | 1.977 ± 122 | 1.301 ± 93 |
| ng*hr/mL | Normal Hepatic Function: Crizotinib 250 mg Twice Daily | Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily | Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily | Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily | Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily | Severe Hepatic Impairment Crizotinib 250 mg Once Daily |
|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration Time Curve as Daily Exposure (AUCdaily) of Crizotinib: Cycle 2 Day 1 | 7107 ± 48 | 5422 ± 66 | 6476 ± 73 | 2305 ± 83 | 8108 ± 58 | 4596 ± 63 |
| ng*hr/mL | Normal Hepatic Function: Crizotinib 250 mg Twice Daily | Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily | Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily | Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily | Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily | Severe Hepatic Impairment Crizotinib 250 mg Once Daily |
|---|---|---|---|---|---|---|
| Unbound Area Under the Plasma Concentration Time Curve as Daily Exposure (AUCdaily) of Crizotinib: Cycle 2 Day 1 | 257.7 ± 38 | 166.1 ± 73 | 279.4 ± 95 | 124.6 ± 85 | 337.0 ± 59 | 161.9 ± 48 |
AUCdaily of PF-06260182, (a metabolite of Crizotinib) is reported in this outcome measure.
| ng*hr/mL | Normal Hepatic Function: Crizotinib 250 mg Twice Daily | Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily | Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily | Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily | Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily | Severe Hepatic Impairment Crizotinib 250 mg Once Daily |
|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration Time Curve as Daily Exposure (AUCdaily) of PF-06260182: Cycle 2 Day 1 | 2173 ± 43 | 1435 ± 81 | 961.2 ± 168 | 200.0 ± 48 | 784.0 ± 117 | 434.0 ± 96 |
Unbound AUCdaily of PF-06260182, (a metabolite of Crizotinib) is reported in this outcome measure, where AUCdaily was area under the plasma concentration time curve as daily exposure post-dose.
| ng*hr/mL | Normal Hepatic Function: Crizotinib 250 mg Twice Daily | Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily | Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily | Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily | Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily | Severe Hepatic Impairment Crizotinib 250 mg Once Daily |
|---|---|---|---|---|---|---|
| Unbound Area Under the Plasma Concentration Time Curve as Daily Exposure (AUCdaily) of PF-06260182: Cycle 2 Day 1 | 82.56 ± 36 | 54.85 ± 99 | 46.66 ± 181 | 11.56 ± 49 | 39.41 ± 119 | 22.49 ± 79 |
An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability or incapacity, congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 4 years that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious adverse events.
| participants | Normal Hepatic Function: Crizotinib 250 mg Twice Daily | Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily | Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily | Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily | Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily | Severe Hepatic Impairment Crizotinib 250 mg Once Daily |
|---|---|---|---|---|---|---|
| AEs | 11 | 15 | 20 | 9 | 16 | 16 |
| SAEs | 7 | 8 | 13 | 6 | 14 | 14 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AE was assessed according to severity grading based on National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events \[CTCAE\] Version 4.0. Grade 1 =mild; Grade 2 =moderate; Grade 3 =severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated; Grade 4 =life-threatening or disabling, urgent intervention indicated; Grade 5 =death. Treatment-emergent events were events between first dose of study drug and up to 4 years that were absent before treatment that worsened relative to pretreatment state. If the same participant in a given treatment had more than 1 adverse event, only the maximum CTCAE was reported.
| participants | Normal Hepatic Function: Crizotinib 250 mg Twice Daily | Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily | Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily | Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily | Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily | Severe Hepatic Impairment Crizotinib 250 mg Once Daily |
|---|---|---|---|---|---|---|
| Grade 1 AEs | 1 | 2 | 2 | 0 | 0 | 0 |
| Grade 2 AEs | 2 | 6 | 5 | 1 | 0 | 1 |
| Grade 3 AEs | 6 | 3 | 5 | 2 | 9 | 8 |
| Grade 4 AEs | 0 | 1 | 2 | 1 | 2 | 0 |
| Grade 5 AEs | 2 | 3 | 6 | 5 | 5 | 7 |
Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both serious and non-serious adverse events.
| participants | Normal Hepatic Function: Crizotinib 250 mg Twice Daily | Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily | Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily | Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily | Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily | Severe Hepatic Impairment Crizotinib 250 mg Once Daily |
|---|---|---|---|---|---|---|
| AE | 9 | 14 | 15 | 6 | 11 | 11 |
| SAE | 0 | 3 | 0 | 0 | 0 | 0 |
Anemia(grade\[g\]1:Less than\[\<\] Lower limit of normal\[LLN\] to 10gram per\[/\] deciliter\[g/dL\],g2:\<10 to 8g/dL,g3:\<8g/dL,g4:lifethreatening);platelet (g1:\<LLN to 75\*10\^3/millimeter\[mm\]\^3,g2:\<75\*10\^3/mm\^3 to 50\*10\^3/mm\^3,g3:\<50\*10\^3/mm\^3 to 25\*10\^3/mm\^3,g4:\<25\*10\^3/mm\^3);lymphopenia(g1:\<LLN to 8\*10\^2/mm\^3,g2:\<8\*10\^2 to 5\*10\^2/mm\^3,g3:\<5\*10\^2 to 2\*10\^2/mm\^3,g4:\<2\*10\^2/mm\^3);neutrophil (Absolute)(g1:\<LLN to 15\*10\^2/mm\^3,g2:\<15\*10\^2 to 10\*10\^2/mm\^3,g3:\<10\*10\^2 to 5\*10\^2/mm\^3,g4:\<5\*10\^2/mm\^3);white blood cell count(g1:\<LLN to 3\*10\^3/mm\^3,g2:\<3\*10\^3 to 2\*10\^3/mm\^3,g3:\<2\*10\^3 to 1\*10\^3/mm\^3,g4:\<1\*10\^3/mm\^3);hemoglobin(g1:increase in hemoglobin level\>0 to 2 g/dL above ULN or above baseline if baseline is above ULN,g2:increase in hemoglobin level\>2 to 4g/dL above ULN or above baseline if baseline is above ULN,g3:increase in hemoglobin level\>4 g/dL above ULN or above baseline if baseline is above ULN). Only categories with atleast 1 participant with abnormality are reported in this outcome measure.
| participants | Normal Hepatic Function: Crizotinib 250 mg Twice Daily | Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily | Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily | Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily | Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily | Severe Hepatic Impairment Crizotinib 250 mg Once Daily |
|---|---|---|---|---|---|---|
| Anemia: Grade 1 | 4 | 7 | 9 | 9 | 7 | 8 |
| Anemia: Grade 2 | 4 | 7 | 4 | 1 | 5 | 5 |
| Anemia: Grade 3 | 1 | 1 | 3 | 0 | 1 | 1 |
| Hemoglobin Increased: Grade 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Lymphopenia: Grade 1 | 2 | 2 | 5 | 2 | 0 | 1 |
| Lymphopenia: Grade 2 | 3 | 7 | 4 | 6 | 9 | 7 |
| Lymphopenia: Grade 3 | 1 | 1 | 3 | 2 | 2 | 4 |
| Lymphopenia: Grade 4 | 0 | 0 | 0 | 0 | 2 | 0 |
| Neutrophils (Absolute): Grade 1 | 0 | 0 | 1 | 2 | 1 | 2 |
| Neutrophils (Absolute): Grade 2 | 3 | 1 | 2 | 0 | 3 | 0 |
| Neutrophils (Absolute): Grade 3 | 0 | 0 | 1 | 0 | 1 | 3 |
| Platelets: Grade 1 | 0 | 2 | 4 | 2 | 8 | 3 |
| Platelets: Grade 2 | 0 | 0 | 1 | 0 | 2 | 2 |
| Platelets: Grade 3 | 0 | 0 | 2 | 3 | 2 | 5 |
| White Blood Cells: Grade 1 | 2 | 3 | 4 | 2 | 2 | 1 |
| White Blood Cells: Grade 2 | 1 | 1 | 3 | 2 | 3 | 3 |
| White Blood Cells: Grade 3 | 0 | 0 | 0 | 0 | 1 | 3 |
ALT/AST(grade\[g\]1:\>ULN-3\*ULN,g2:\>3-5\*ULN,g3:\>5-20\*ULN,g4:\>20\*ULN);AP(g1:\>ULN-2.5\*ULN,g2:\>2.5-5\*ULN,g3:\>5-20\*ULN,g4:\>20\*ULN);CR(g1:\>ULN-1.5\*ULN,g2:\>1.5-3\*ULN,g3:\>3-6\*ULN,g4:\>6\*ULN);hyperglycemia(g1:\>ULN-160mg/dL,g2:\>160-250mg/dL,g3:\>250-500mg/dL,g4:\>500mg/dL);bilirubin(total)(g1:\>ULN-1.5\*ULN,g2:\>1.5-3\*ULN,g3:\>3-10\*ULN,g4:\>10\*ULN);hypoglycemia(g1:\<LLN-55mg/dL,g2:\<55-40mg/dL,g3:\<40-30mg/dL,g4:\<30mg/dL);hyperkalemia(g1:\>ULN-5.5mmol/L,g2:\>5.5-6mmol/L,g3:\>6-7mmol/L,g4:\>7mmol/L);hypokalemia(g1:\<LLN-3mmol/L,g2:\<LLN-3mmol/L,g3:\<3-2.5mmol/L,g4:\<2.5mmol/L);hypermagnesemia(g1:\>ULN-3mg/dL,g3:\>3-8mg/dL,g4:\>8mg/dL);hypocalcemia(g1:\<LLN-8mg/dL,g2:\<8-7mg/dL,g3:\<7-6mg/dL,g4:\<6mg/dL);hypomagnesemia(g1:\<LLN-1.2mg/dL,g2:\<1.2-0.9mg/dL,g3:\<0.9-0.7mg/dL,g4:\<0.7mg/dL);hyponatremia(g1:\<LLN-130mmol/L,g3:\<130-120mmol/L,g4:\<120mmol/L);hypoalbuminemia(g1:\<LLN-3g/dL,g2:\<3-2g/dL,g3:\<2g/dL,g4:lifethreatening);hypophosphatemia(g1:\<LLN-2.5mg/dL,g2:\<2.5-2mg/dL,g3:\<2-1mg/dL,g4:\<1mg/dL).Participant\>=1abnormality given.
| participants | Normal Hepatic Function: Crizotinib 250 mg Twice Daily | Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily | Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily | Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily | Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily | Severe Hepatic Impairment Crizotinib 250 mg Once Daily |
|---|---|---|---|---|---|---|
| Alanine aminotransferase (ALT): Grade 1 | 8 | 3 | 12 | 6 | 12 | 9 |
| ALT: Grade 2 | 0 | 0 | 5 | 2 | 3 | 5 |
| ALT: Grade 3 | 0 | 0 | 0 | 1 | 1 | 0 |
| Alkaline phosphatase(AP): Grade 1 | 4 | 7 | 8 | 4 | 7 | 5 |
| Alkaline phosphatase: Grade 2 | 2 | 1 | 5 | 3 | 4 | 4 |
| Alkaline phosphatase: Grade 3 | 0 | 1 | 3 | 3 | 4 | 6 |
| AST:Grade 1 | 6 | 7 | 8 | 5 | 4 | 4 |
| AST: Grade 2 | 1 | 0 | 7 | 0 | 7 | 3 |
| AST: Grade 3 | 0 | 1 | 3 | 5 | 5 | 7 |
| AST: Grade 4 | 0 | 0 | 0 | 0 | 0 | 2 |
| Bilirubin (total): Grade 1 | 1 | 0 | 2 | 0 | 0 | 0 |
| Bilirubin (total): Grade 2 | 1 | 0 | 3 | 1 | 7 | 0 |
| Bilirubin (total): Grade 3 | 0 | 0 | 2 | 5 | 8 | 10 |
| Bilirubin (total): Grade 4 | 0 | 0 | 2 | 3 | 1 | 6 |
| Creatinine (CR): Grade 1 | 9 | 11 | 8 | 6 | 6 | 10 |
| CR: Grade 2 | 2 | 4 | 7 | 3 | 8 | 5 |
| CR: Grade 3 | 0 | 0 | 1 | 0 | 1 | 1 |
| Hyperglycemia: Grade 1 | 5 | 8 | 10 | 8 | 5 | 8 |
| Hyperglycemia: Grade 2 | 1 | 2 | 5 | 0 | 4 | 2 |
| Hyperglycemia: Grade 3 | 0 | 1 | 1 | 0 | 0 | 4 |
| Hyperkalemia: Grade 1 | 2 | 1 | 4 | 2 | 3 | 1 |
| Hyperkalemia: Grade 2 | 0 | 0 | 1 | 0 | 0 | 0 |
| Hyperkalemia: Grade 3 | 0 | 0 | 1 | 0 | 1 | 0 |
| Hypermagnesemia: Grade 1 | 1 | 1 | 4 | 0 | 2 | 3 |
| Hypoalbuminemia: Grade 1 | 5 | 4 | 2 | 1 | 0 | 0 |
| Hypoalbuminemia: Grade 2 | 5 | 10 | 9 | 8 | 14 | 8 |
| Hypoalbuminemia: Grade 3 | 0 | 0 | 3 | 1 | 2 | 7 |
| Hypocalcemia: Grade 1 | 5 | 11 | 5 | 3 | 4 | 7 |
| Hypocalcemia: Grade 2 | 3 | 1 | 9 | 4 | 9 | 9 |
| Hypoglycemia: Grade 1 | 0 | 0 | 2 | 0 | 2 | 2 |
| Hypokalemia: Grade 1 | 4 | 1 | 5 | 0 | 5 | 4 |
| Hypokalemia: Grade 3 | 0 | 0 | 0 | 1 | 0 | 0 |
| Hypomagnesemia: Grade 1 | 0 | 2 | 5 | 3 | 4 | 6 |
| Hyponatremia: Grade 1 | 5 | 5 | 4 | 5 | 7 | 8 |
| Hyponatremia: Grade 3 | 1 | 4 | 7 | 5 | 7 | 7 |
| Hypophosphatemia: Grade 1 | 0 | 3 | 1 | 0 | 0 | 1 |
| Hypophosphatemia: Grade 2 | 1 | 2 | 3 | 3 | 3 | 3 |
| Hypophosphatemia: Grade 3 | 2 | 0 | 1 | 1 | 3 | 1 |
Criteria for abnormal value of ECG parameters: maximum increase from baseline (IFB) in QT interval using Fridericia's correction (QTcF)/QT interval using Bazett's correction (QTcB) range from less than (\<)30 millisecond (msec), 30 to \<60, greater than or equal to (\>=)60 msec; maximum post-dose QTcF/QTcB ranges from \<450 msec, 450 to \<480 msec, 480 to \<500, and \>=500 msec; PR interval: \>=50 percent (%) increase when baseline \<200 msec; or increase \>=25% when baseline less than or equal to (\<=)200 msec; QRS interval: \>=50% increase when baseline \<100 msec; \>=25% increase when baseline \>=100 msec. Only categories which included atleast 1 participant with abnormality are reported in this outcome measure.
| participants | Normal Hepatic Function: Crizotinib 250 mg Twice Daily | Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily | Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily | Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily | Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily | Severe Hepatic Impairment Crizotinib 250 mg Once Daily |
|---|---|---|---|---|---|---|
| Maximum Post-dose QTCF Interval: <450 msec | 9 | 13 | 13 | 8 | 11 | 6 |
| Maximum Post-dose QTCF Interval: 450 to <480 msec | 1 | 2 | 6 | 1 | 5 | 9 |
| Maximum Post-dose QTCF Interval: 480 to <500 msec | 1 | 0 | 0 | 1 | 0 | 1 |
| Maximum Post-dose QTCF Interval: >=500 msec | 0 | 0 | 1 | 0 | 0 | 0 |
| Maximum Post-dose QTCB Interval: <450 msec | 10 | 13 | 12 | 7 | 11 | 5 |
| Maximum Post-dose QTCB Interval: 450 to <480 msec | 0 | 2 | 7 | 2 | 5 | 8 |
| Maximum Post-dose QTCB Interval: 480 to <500 msec | 1 | 0 | 0 | 1 | 0 | 1 |
| Maximum Post-dose QTCB Interval: >=500 msec | 0 | 0 | 1 | 0 | 0 | 2 |
| Maximum QTCF Interval IFB: <30 msec | 7 | 12 | 11 | 7 | 7 | 8 |
| Maximum QTCF Interval IFB: 30 to 60 msec | 2 | 1 | 1 | 0 | 4 | 1 |
| Maximum QTCF IFB: >=60 msec | 0 | 0 | 0 | 1 | 0 | 1 |
| Maximum QTCB Interval IFB: <30 msec | 7 | 10 | 8 | 5 | 7 | 7 |
| Maximum QTCB Interval IFB: 30 to 60 msec | 0 | 1 | 0 | 1 | 1 | 1 |
| Maximum QTCB Interval IFB: >=60 msec | 0 | 0 | 0 | 1 | 0 | 1 |
| Maximum PR Interval IFB: >=50% | 0 | 1 | 0 | 0 | 0 | 0 |
| Maximum PR Interval IFB, Other Than: >=25 or 50% | 10 | 14 | 19 | 10 | 15 | 16 |
| Maximum QRS Interval IFB, Other Than: >=25 or 50% | 11 | 15 | 20 | 10 | 16 | 16 |
Fundoscopy examination included an examination of the vitreous body, retina macula, retina non-macula, optic nerve head, optic disc notching and fundus using the category of the examination status (normal, mild, moderate, or severe). In this outcome measure, number of participants with abnormal fundoscopy values identified by investigator were reported.
| participants | Normal Hepatic Function: Crizotinib 250 mg Twice Daily | Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily | Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily | Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily | Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily | Severe Hepatic Impairment Crizotinib 250 mg Once Daily |
|---|---|---|---|---|---|---|
| Right Eye, Retina Macula: Mild Abnormality | 0 | 0 | 1 | 0 | 0 | 0 |
| Right Eye, Retina Non-Macula: Mild Abnormality | 1 | 0 | 0 | 0 | 0 | 0 |
| Right Eye, Optic Disc Notching: Mild Abnormality | 1 | 1 | 0 | 0 | 0 | 0 |
| Right Eye, Fundus: Mild Abnormality | 0 | 0 | 1 | 0 | 0 | 0 |
| Right Eye, Vitreous Body: Mild Abnormality | 0 | 0 | 0 | 1 | 0 | 0 |
| Left Eye, Retina Non-Macula: Mild Abnormality | 1 | 0 | 0 | 0 | 1 | 0 |
| Left Eye, Vitreous Body: Mild Abnormality | 1 | 0 | 0 | 1 | 0 | 0 |
| Left Eye, Fundus: Mild Abnormality | 0 | 0 | 1 | 0 | 0 | 0 |
| Left Eye, Retina Macula: Mild Abnormality | 0 | 0 | 1 | 0 | 0 | 0 |
| Left Eye, Optic Disc Notching: Mild Abnormality | 1 | 0 | 0 | 0 | 0 | 0 |
ORR was defined as percentage of participants with confirmed complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumors (RECIST) version 1.1. In case of target lesions CR was defined as the disappearance of all target lesions and in case nodal disease included in the sum of target lesions. The nodes decreased to normal size (\<10 mm). In case of non-target lesions disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10 mm short axis). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Confirmed responses were those who persisted on repeat imaging study at least 4 weeks after the initial documentation of response.
| percentage of participants | Normal Hepatic Function: Crizotinib 250 mg Twice Daily | Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily | Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily | Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily | Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily | Severe Hepatic Impairment Crizotinib 250 mg Once Daily |
|---|---|---|---|---|---|---|
| Objective Response Rate (ORR) | 9.1 (0.2 to 41.3) | 0 (0.0 to 21.8) | 5.0 (0.1 to 24.9) | 0 (0.0 to 30.8) | 6.3 (0.2 to 30.2) | 0 (0.0 to 20.6) |
DR was defined as the time from date of first documentation of CR or PR to first documentation of objective tumor progression or death due to any cause, whichever occurred first. In case of target lesions CR was defined as the disappearance of all target lesions and in case nodal disease included in the sum of target lesions. The nodes decreased to normal size (\<10 mm). In case of non-target lesions disappearance of all non-target lesions and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Objective tumor progression as per RECIST version 1.1 was defined as \>=20% increase in sum of diameters of target lesions taking as a reference smallest sum of diameters recorded since treatment started, or appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. DR was estimated using Kaplan-Meier method.
| week | Normal Hepatic Function: Crizotinib 250 mg Twice Daily | Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily | Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily | Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily | Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily | Severe Hepatic Impairment Crizotinib 250 mg Once Daily |
|---|---|---|---|---|---|---|
| Duration of Response (DR) | NA (NA to NA) | — | 17.4 (NA to NA) | — | NA (NA to NA) | — |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Normal Hepatic Function: Crizotinib 250 mg Twice Daily | 3/11 (27.3%) | 7/11 (63.6%) | 11/11 (100%) |
| Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily | 4/15 (26.7%) | 8/15 (53.3%) | 15/15 (100%) |
| Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily | 8/20 (40%) | 13/20 (65%) | 20/20 (100%) |
| Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily | 5/10 (50%) | 6/10 (60%) | 9/10 (90%) |
| Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily | 7/16 (43.8%) | 14/16 (87.5%) | 16/16 (100%) |
| Severe Hepatic Impairment Crizotinib 250 mg Once Daily | 9/16 (56.3%) | 14/16 (87.5%) | 16/16 (100%) |
| Event | Normal Hepatic Function: Crizotinib 250 mg Twice Daily | Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily | Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily | Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily | Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily | Severe Hepatic Impairment Crizotinib 250 mg Once Daily |
|---|---|---|---|---|---|---|
| Disease progressionGeneral disorders | 2/11 | 2/15 | 4/20 | 5/10 | 4/16 | 6/16 |
| AscitesGastrointestinal disorders | 0/11 | 0/15 | 0/20 | 2/10 | 2/16 | 4/16 |
| Hepatic encephalopathyNervous system disorders | 0/11 | 0/15 | 1/20 | 2/10 | 2/16 | 2/16 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 0/11 | 2/15 | 0/20 | 0/10 | 0/16 | 0/16 |
| Atrial fibrillationCardiac disorders | 0/11 | 0/15 | 0/20 | 0/10 | 2/16 | 0/16 |
| Hepatic failureHepatobiliary disorders | 0/11 | 0/15 | 0/20 | 0/10 | 2/16 | 0/16 |
| PneumoniaInfections and infestations | 0/11 | 1/15 | 1/20 | 0/10 | 1/16 | 2/16 |
| Confusional statePsychiatric disorders | 0/11 | 0/15 | 0/20 | 0/10 | 2/16 | 0/16 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/11 | 0/15 | 0/20 | 1/10 | 2/16 | 0/16 |
| Small intestinal obstructionGastrointestinal disorders | 0/11 | 0/15 | 0/20 | 1/10 | 1/16 | 0/16 |
| Event | Normal Hepatic Function: Crizotinib 250 mg Twice Daily | Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily | Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily | Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily | Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily | Severe Hepatic Impairment Crizotinib 250 mg Once Daily |
|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 7/11 | 4/15 | 5/20 | 1/10 | 1/16 | 1/16 |
| NauseaGastrointestinal disorders | 7/11 | 8/15 | 11/20 | 2/10 | 7/16 | 6/16 |
| HyponatraemiaMetabolism and nutrition disorders | 0/11 | 6/15 | 5/20 | 6/10 | 4/16 | 6/16 |
| VomitingGastrointestinal disorders | 4/11 | 8/15 | 6/20 | 2/10 | 9/16 | 3/16 |
| ConstipationGastrointestinal disorders | 6/11 | 2/15 | 4/20 | 1/10 | 4/16 | 2/16 |
| FatigueGeneral disorders | 4/11 | 6/15 | 4/20 | 5/10 | 8/16 | 7/16 |
| HyperbilirubinaemiaHepatobiliary disorders | 0/11 | 0/15 | 4/20 | 2/10 | 8/16 | 0/16 |
| Blood bilirubin increasedInvestigations | 0/11 | 0/15 | 2/20 | 5/10 | 1/16 | 1/16 |
| Blood creatinine increasedInvestigations | 5/11 | 4/15 | 5/20 | 4/10 | 3/16 | 3/16 |
| HypophosphataemiaMetabolism and nutrition disorders | 1/11 | 2/15 | 1/20 | 4/10 | 2/16 | 2/16 |
Safety analysis population included all enrolled participants who received at least 1 dose of Crizotinib on Cycle 1, Day 1.
| Age, Continuous(years) | Normal Hepatic Function: Crizotinib 250 mg Twice Daily | Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily | Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily | Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily | Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily | Severe Hepatic Impairment Crizotinib 250 mg Once Daily | Total |
|---|---|---|---|---|---|---|---|
| Mean | 57.7 ± 15.64 | 62.9 ± 10.35 | 61.2 ± 10.14 | 59.2 ± 8.85 | 60.3 ± 7.87 | 59.0 ± 6.04 | 60.3 ± 9.77 |
| Sex: Female, Male(Participants) | Normal Hepatic Function: Crizotinib 250 mg Twice Daily | Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily | Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily | Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily | Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily | Severe Hepatic Impairment Crizotinib 250 mg Once Daily | Total |
|---|---|---|---|---|---|---|---|
| Female | 4 | 6 | 7 | 2 | 6 | 6 | 31 |
| Male | 7 | 9 | 13 | 8 | 10 | 10 | 57 |
Ran from Jul 2012 to primary completion in Jun 2016, 47 months.
Results were first posted in Oct 2018, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Crizotinib